| Literature DB >> 33920829 |
Man You1, Jianping Xu1.
Abstract
Hybridization between more divergent organisms is likely to generate progeny with more novel genetic interactions and genetic variations. However, the relationship between parental genetic divergence and progeny phenotypic variation remains largely unknown. Here, using strains of the human pathogenic Cryptococcus, we investigated the patterns of such a relationship. Twenty-two strains with up to 15% sequence divergence were mated. Progeny were genotyped at 16 loci. Parental strains and their progeny were phenotyped for growth ability at two temperatures, melanin production at seven conditions, and susceptibility to the antifungal drug fluconazole. We observed three patterns of relationships between parents and progeny for each phenotypic trait, including (i) similar to one of the parents, (ii) intermediate between the parents, and (iii) outside the parental phenotypic range. We found that as genetic distance increases between parental strains, progeny showed increased fluconazole resistance and growth at 37 °C but decreased melanin production under various oxidative and nitrosative stresses. Our findings demonstrate that, depending on the traits, both evolutionarily more similar strains and more divergent strains may be better parents to generate progeny with hybrid vigor. Together, the results indicate the enormous potential of Cryptococcus hybrids in their evolution and adaptation to diverse conditions.Entities:
Keywords: Cryptococcus hybrids; better-parent heterosis; genotypic diversity; phenotypic variation; transgressive segregation
Year: 2021 PMID: 33920829 PMCID: PMC8071107 DOI: 10.3390/jof7040299
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X
Strains of the C. neoformans species complex (CNSC) and C. gatii species complex (CGSC) were used as parents in this study.
| Species Complex | Lineage | Isolate ID | Mating Type | Source |
|---|---|---|---|---|
| CGSC | VGI | B4495 |
| Clinical |
| B4545 |
| Clinical | ||
| WM179 |
| Human, CSF | ||
| WM276 |
|
| ||
| R794 |
| Human, CSF | ||
| R299 |
| Human, CSF | ||
| VGII | LA55 |
| Human, CSF | |
| R265 |
| Human, BAL | ||
| LA61 |
| Human, CSF | ||
| KB5746 |
| Horse | ||
| VGIII | B4546 |
| Clinical | |
| JF109 |
| Lab strain | ||
| ATCC32608 |
| Human, CSF | ||
| B4544 |
| Clinical | ||
| JF101 |
| Lab strain | ||
| B4499 |
| Clinical | ||
| VGIV | WM779 |
| Cheetah | |
| CNSC | VNI | KN99 |
| Lab strain |
| KN99 |
| Lab strain | ||
| CDC15 |
| Clinical | ||
| VNIV | JEC20 |
| Lab strain | |
| JEC21 |
| Lab strain |
Details of primers, polymerase chain reaction (PCR) protocols, and restriction enzymes that were used in this study.
| Genes | Primer Sequences (5′–3′) | Amplification Conditions | Restriction Enzymes |
|---|---|---|---|
|
| F: CTGAGGAATCTCAAACCAGGGA | 94 °C 4 min; 35 cycles: 94 °C 45 s, | NA |
| R: CCAGGGCATCTAGAAACAATCG | |||
|
| F: GATCTCTCTCAGCAGGCCAC | NA | |
| R: AAATATCAGCTGCCCAGGTGA | |||
|
| F: TATGATGGCCGTAGCGCTATC | 94 °C 4 min; 35 cycles: 94 °C 1 min, | PvuII |
| R: TGGTGGTACTCCTGCCATTG | |||
|
| F: GGGAGAATTTGATTCAAGTGCAAC | SacI | |
| R: ATGATGTTGCATCTGGCATCATAC | |||
|
| F: CCACCGAACCCTTCTAGGATA | 94 °C 3 min; 35 cycles: 94 °C 45 s, | NA |
| R: CTTCTTGGCACCTCCCTTGAG | |||
|
| F: AACATGTTCCCTGGGCCTGTG | 94 °C 3 min; 30 cycles: 94 °C 30 s, | NA |
| R: ATGAGAATTGAATCGCCTTGT | |||
|
| F: CTTCAGGCGGAGAGAGGTTT | 94 °C 3 min; 30 cycles: 94 °C 45 s, | NA |
| R: GATTTGGCGTTGGTTTCAGT | |||
|
| F: ATCCTTTGCAGACGACTTGA | 94 °C 3 min; 35 cycles: 94 °C 30 s, | NA |
| R: GTGATCAGTGCATTGCATGA | |||
|
| F: ATGTCCTCCCA AGCCCTCGAC | 94 °C 3 min; 35 cycles: 94 °C 45 s, | HhaI |
| R: TTAAGACCTCT GAACACCGTACTC | |||
|
| F: CTCTACGTCGAGCAAGTCAAG | 94 °C 3 min; 35 cycles: 94 °C 30 s, | HinfI |
| R: TCCGCTGCACAAGTGATACCC | |||
|
| F: TTAATGGACTGGGCAGATGCTCGTC | 94 °C 4 min; 36 cycles: 94 °C 45 s, | HhaI |
| R: ATGTCTTCTCCCGCCCTTTTTGCC | |||
|
| F: GAGCGACATCGTCCCTATGTGA | HinfI | |
| R: ACTGGTAGCAATGGCGACATG | |||
|
| F: ACGCACTCTCACAGCTCCTTCG | HpyCH4IV | |
| R: GCAAAGCTCAGGCTCAAATCCAG | |||
|
| F: GCTCAAGAACCATACCTGCTCAT | Sau96I/HpyAV | |
| R: GGCGGCAGGTGACTTCAGTG | |||
|
| F: TGCGAGTCGAAGGCRGACTATGATCGTCTGATTGC | 94 °C 4 min; 36 cycles: 94 °C 45 s, | HinfI |
| R: GCTGGATCCGTTCCTTGATAGCRGCCCACTTTGCG | |||
|
| F: AGCATCGTCGATGGACATCKTGGACCTTCTTCGCC | HpyCH4IV | |
| R: CAGAGAGCCCAGACRAAGGAGGCGAGGAACATGGC | |||
|
| F: CTTTGGGTGGAAAGATTTCTCAAGTCTCTGCCGAG | AluI/Sau3A | |
| R: GCGGCGGCAAATCCCTTTTCRTCGTGCCATCGGGC | |||
|
| F: AGGCCCCGAGGTTGTTGCCGARGCTGTCCGAG | AccI | |
| R: TCGGGGGCACCGGCGAGAGACGCAGARGGGAGGAG | |||
|
| F: AGTGCTCAGAGTCTGGGGCTGG | HincII | |
| R: GCCATTCGCAGGGGTGGAGG | |||
|
| F: TGGCGTCTCTTTGAACGCGATC | HaeII | |
| F: ATGGCGGAATGTCCGGCTTT | |||
|
| F: TTGGATCGCTTGCTCGCGAA | XhoI | |
| R: AGGCCCGAGCAAAGGAATGA |
Figure 1Chromosomal locations of the fourteen polymerase chain reaction-restriction length polymorphism (PCR-RFLP) markers that were used for progeny genotyping in this study. These markers were located across 10 chromosomes (out of 14) on the four reference genomes of strains, KN99 (VNI lineage), JEC21 (VNIV lineage), R265 (VGII lineage), and WM276 (VGI lineage). Dark text indicates the location of centromeres.
Information on crosses, the genetic distance between parental strains, ploidy levels of progeny, multilocus genotypes (MLG), and minimum inhibitory concentration (MIC) values to fluconazole.
| Group | Cross | Genetic Distance | Progeny ID | Ploidy | Genotype | MIC | ||
|---|---|---|---|---|---|---|---|---|
| Intra-lineage | VGIIIxVGIII | B4546 (VGIII) MIC = 1 | B4544 (VGIII) MIC = 4 | 0.005 | YMA79 | A | NA | 4 |
| 0.005 | YMA80 | A | NA | 4 | ||||
| 0.005 | YMD81 | D | NA | 4 | ||||
| JF109 (VGIII) MIC = 2 | B4544 (VGIII) MIC = 4 | 0.005 | YMA62 | A | NA | 8 | ||
| 0.005 | YMA63 | A | NA | 8 | ||||
| 0.005 | YMA64 | A | NA | 8 | ||||
| ATCC32608 (VGIII) MIC = 4 | B4544 (VGIII) MIC = 4 | 0.005 | YMA65 | A | NA | 8 | ||
| 0.005 | YMA66 | A | NA | 8 | ||||
| 0.005 | YMA68 | A | NA | 8 | ||||
| B4546 (VGIII) MIC = 1 | JF101 (VGIII) MIC = 4 | 0.009 | YMA73 | A | NA | 4 | ||
| 0.009 | YMA74 | A | NA | 4 | ||||
| 0.009 | YMA138 | A | NA | 2 | ||||
| JF109 (VGIII) MIC =2 | JF101 (VGIII) MIC = 4 | 0.009 | YMA102 | A | NA | 4 | ||
| 0.009 | YMA125 | A | NA | 4 | ||||
| 0.009 | YMA136 | A | NA | 1 | ||||
| ATCC32608 (VGIII) MIC = 4 | JF101 (VGIII) MIC = 4 | 0.009 | YMA77 | A | NA | 4 | ||
| 0.009 | YMA78 | A | NA | 4 | ||||
| 0.009 | YMA105 | A | NA | 4 | ||||
| Inter-lineage | VGIxVGIII | B4495 (VGI) MIC = 2 | B4544 (VGIII) MIC = 4 | 0.033 | YMD53 | D | MLG.21 | 4 |
| 0.033 | YMD90 | D | MLG.19 | 2 | ||||
| 0.033 | YMD96 | D | MLG.12 | 4 | ||||
| B4495 (VGI) MIC = 2 | JF101 (VGIII) MIC = 4 | 0.038 | YMD69 | D | MLG.20 | 4 | ||
| 0.038 | YMA71 | A | MLG.20 | 4 | ||||
| 0.038 | YMD72 | D | MLG.20 | 4 | ||||
| B4545 (VGI) MIC = 2 | JF101 (VGIII) MIC = 4 | 0.04 | YMD85 | D | MLG.18 | 4 | ||
| 0.04 | YMD86 | D | MLG.17 | 4 | ||||
| VGIVxVGIII | JF109 (VGIII) MIC = 2 | WM779 (VGIV) MIC = 2 | 0.045 | YMD36 | D | MLG.11 | 2 | |
| VGIIxVGIII | LA55 (VGII) MIC = 32 | JF101 (VGIII) MIC = 4 | 0.128 | YMD111 | D | MLG.13 | 8 | |
| B4546 (VGIII) MIC = 1 | R265 (VGII) MIC = 4 | 0.135 | YMD132 | D | MLG.8 | 8 | ||
| 0.135 | YMD135 | D | MLG.8 | 8 | ||||
| 0.135 | YMD150 | D | MLG.7 | 8 | ||||
| VNIxVGIII | JF109 (VGIII) MIC = 2 | KN99α (VNI) MIC = 1 | 0.17 | YMD112 | D | MLG.5 | 4 | |
| 0.17 | YMD113 | D | MLG.5 | 8 | ||||
| 0.17 | YMD114 | D | MLG.5 | 8 | ||||
| B4546 (VGIII) MIC = 1 | KN99α (VNI) MIC = 1 | 0.17 | YMD29 | D | MLG.5 | 4 | ||
| 0.17 | YMT33 | T | MLG.5 | 4 | ||||
| KN99a (VNI) MIC = 1 | JF101 (VGIII) MIC = 4 | 0.171 | YMD1 | D | MLG.1 | 1 | ||
| 0.171 | YMD5 | D | MLG.1 | 2 | ||||
| 0.171 | YMD10 | D | MLG.1 | 2 | ||||
| JF109 (VGIII) MIC = 2 | CDC15 (VNI) MIC = 32 | 0.172 | YMA162 | A | MLG.4 | 16 | ||
| 0.172 | YMD164 | D | MLG.6 | 32 | ||||
| 0.172 | YMD165 | D | MLG.4 | 16 | ||||
| B4546 (VGIII) MIC = 1 | CDC15 (VNI) MIC = 32 | 0.172 | YMD34 | D | MLG.4 | 16 | ||
| 0.172 | YMD83 | D | MLG.2 | 16 | ||||
| 0.172 | YMT98 | T | MLG.3 | 4 | ||||
| VNIVxVGIII | JF109 (VGIII) MIC = 2 | JEC21 (VNIV) MIC = 1 | 0.172 | YMD87 | D | MLG.9 | 4 | |
| B4546 (VGIII) MIC = 1 | JEC21 (VNIV) MIC = 1 | 0.172 | YMD88 | D | MLG.10 | 4 | ||
| 0.172 | YMD89 | D | MLG.9 | 4 | ||||
| JEC20 (VNIV) MIC = 1 | JF101 (VGIII) MIC = 4 | 0.173 | YMD16 | D | MLG.15 | 4 | ||
| 0.173 | YMD17 | D | MLG.16 | 4 | ||||
| JEC20 (VNIV) MIC = 1 | B4544 (VGIII) MIC = 4 | 0.171 | YMD11 | D | MLG.14 | 8 | ||
| 0.171 | YMD12 | D | MLG.22 | 8 | ||||
| ATCC32608 (VGIII) MIC = 4 | JEC21 (VNIV) MIC = 1 | 0.171 | YMD25 | D | MLG.10 | 4 | ||
| 0.171 | YMD26 | D | MLG.10 | 4 | ||||
| 0.171 | YMD27 | D | MLG.1 | 4 |
A: aneuploidy; D: diploidy; T: triploidy. NA: genotype was not able to be determined.
Figure 2Three different ploidy levels were observed among progeny. Fluorescence-activated cell sorting (FACS) profiles of haploid control JEC21 (1n), diploid control D14 (2n), likely aneuploid progeny YMA79 (between 1n and 2n), likely diploid progeny YMD135 (2n), and likely triploid progeny YMT98 (between 2n and 4n) are shown here. 1n, 2n, and 4n indicate nuclear DNA content. The x-axis shows the relative fluorescence intensity of DNA content, and the y-axis represents the number of the counted cells of each fluorescence intensity category.
Figure 3Effects of parental genetic divergence on %BPH (better-parent heterosis) in growth (30 °C and 37 °C) and melanin synthesis (non-stress, low oxidative stress, intermediate oxidative stress, high oxidative stress, low nitrosative stress, intermediate nitrosative stress, and high nitrosative stress). The x-axis shows the genetic distance between parental pairs. The y-axis represents the percentage of BPH.